Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units
Methicillin-resistant Staphylococcus aureus (MRSA) causes severe morbidity and mortality in intensive care units (ICUs) worldwide. The purpose of this study was to determine whether intranasal mupirocin prophylaxis is useful to prevent ICU-acquired infections with MRSA. We conducted a 4-year observa...
Gespeichert in:
| Veröffentlicht in: | Critical care (London, England) England), 2005-06, Vol.9 (3), p.R246-R250, Article R246 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | R250 |
|---|---|
| container_issue | 3 |
| container_start_page | R246 |
| container_title | Critical care (London, England) |
| container_volume | 9 |
| creator | Muller, Arno Talon, Daniel Potier, Alexandre Belle, Evelyne Cappelier, Gilles Bertrand, Xavier |
| description | Methicillin-resistant Staphylococcus aureus (MRSA) causes severe morbidity and mortality in intensive care units (ICUs) worldwide. The purpose of this study was to determine whether intranasal mupirocin prophylaxis is useful to prevent ICU-acquired infections with MRSA.
We conducted a 4-year observational retrospective study in a 15-bed adult medical ICU. During the first 2-year period mupirocin ointment was included in the MRSA control programme; during the second, mupirocin was not used. The main endpoint was the number of endogenous ICU-acquired infections with MRSA.
The number of endogenous acquired infections was significantly higher during the second period than during the first (11 versus 1; P = 0.02), although there was no significant difference in the total number of patients infected with MRSA between the two periods. We also observed that nasal MRSA decolonisation was significantly higher in the mupirocin period than in mupirocin-free period (P = 0.002).
Our findings suggest that intranasal mupirocin can prevent endogenous acquired MRSA infection in an ICU. Further double-blind, randomised, placebo-controlled studies are needed to demonstrate its cost-effectiveness and its impact on resistance. |
| doi_str_mv | 10.1186/cc3512 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1175886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67983106</sourcerecordid><originalsourceid>FETCH-LOGICAL-b441t-9a0520dee31b302c8be3d01cc2dd360649eae08c960b16797cd2a2f3192392bc3</originalsourceid><addsrcrecordid>eNp1kktr3DAQx0VpadJt-xGK6aE3t3pYknUplJA-IJBDEuhNyONxV8GWXEleyLePl126TaGnGTSj339ehLxl9CNjrfoEICTjz8g5a5SqFTU_n6--UE3dSiHPyKuc7yllulXiJTlj0rRaGH1Oyl3GKg6VDyW54LIbq2mZfYrgQ1ViNSfcYSjVhGXrwY-jD3XC7HNx6-tNcfP2YYwQAZZcuSXhanwYEIqPYfX2YAzZ77ACl7Bagi_5NXkxuDHjm6PdkLuvl7cX3-ur628_Lr5c1V3TsFIbRyWnPaJgnaAc2g5FTxkA73uhqGoMOqQtGEU7prTR0HPHB8EMF4Z3IDbk84E7L92EPeC-ydHOyU8uPdjovH0aCX5rf8WdZUzLdh3VhpgDoPPxP4CnEYiTPaxi_fvhKJ7i7wVzsZPPgOPoAsYl27XgVjC6F3n_T-J9XFJYB2O5VkJLqeWJBinmnHD4UwSjdn8BJ9l3f_d8SjuuXDwCX1uwzg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>276375575</pqid></control><display><type>article</type><title>Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Muller, Arno ; Talon, Daniel ; Potier, Alexandre ; Belle, Evelyne ; Cappelier, Gilles ; Bertrand, Xavier</creator><creatorcontrib>Muller, Arno ; Talon, Daniel ; Potier, Alexandre ; Belle, Evelyne ; Cappelier, Gilles ; Bertrand, Xavier</creatorcontrib><description>Methicillin-resistant Staphylococcus aureus (MRSA) causes severe morbidity and mortality in intensive care units (ICUs) worldwide. The purpose of this study was to determine whether intranasal mupirocin prophylaxis is useful to prevent ICU-acquired infections with MRSA.
We conducted a 4-year observational retrospective study in a 15-bed adult medical ICU. During the first 2-year period mupirocin ointment was included in the MRSA control programme; during the second, mupirocin was not used. The main endpoint was the number of endogenous ICU-acquired infections with MRSA.
The number of endogenous acquired infections was significantly higher during the second period than during the first (11 versus 1; P = 0.02), although there was no significant difference in the total number of patients infected with MRSA between the two periods. We also observed that nasal MRSA decolonisation was significantly higher in the mupirocin period than in mupirocin-free period (P = 0.002).
Our findings suggest that intranasal mupirocin can prevent endogenous acquired MRSA infection in an ICU. Further double-blind, randomised, placebo-controlled studies are needed to demonstrate its cost-effectiveness and its impact on resistance.</description><identifier>ISSN: 1364-8535</identifier><identifier>EISSN: 1466-609X</identifier><identifier>EISSN: 1364-8535</identifier><identifier>DOI: 10.1186/cc3512</identifier><identifier>PMID: 15987397</identifier><language>eng</language><publisher>England: National Library of Medicine - MEDLINE Abstracts</publisher><subject>Administration, Intranasal ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Cross Infection - prevention & control ; Hospital Mortality ; Humans ; Intensive Care Units ; Length of Stay ; Methicillin Resistance ; Mupirocin - administration & dosage ; Mupirocin - therapeutic use ; Retrospective Studies ; Staphylococcal Infections - prevention & control ; Staphylococcus aureus - isolation & purification</subject><ispartof>Critical care (London, England), 2005-06, Vol.9 (3), p.R246-R250, Article R246</ispartof><rights>Copyright National Library of Medicine - MEDLINE Abstracts Jun 2005</rights><rights>Copyright © 2005 Muller et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b441t-9a0520dee31b302c8be3d01cc2dd360649eae08c960b16797cd2a2f3192392bc3</citedby><cites>FETCH-LOGICAL-b441t-9a0520dee31b302c8be3d01cc2dd360649eae08c960b16797cd2a2f3192392bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175886/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175886/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15987397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muller, Arno</creatorcontrib><creatorcontrib>Talon, Daniel</creatorcontrib><creatorcontrib>Potier, Alexandre</creatorcontrib><creatorcontrib>Belle, Evelyne</creatorcontrib><creatorcontrib>Cappelier, Gilles</creatorcontrib><creatorcontrib>Bertrand, Xavier</creatorcontrib><title>Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units</title><title>Critical care (London, England)</title><addtitle>Crit Care</addtitle><description>Methicillin-resistant Staphylococcus aureus (MRSA) causes severe morbidity and mortality in intensive care units (ICUs) worldwide. The purpose of this study was to determine whether intranasal mupirocin prophylaxis is useful to prevent ICU-acquired infections with MRSA.
We conducted a 4-year observational retrospective study in a 15-bed adult medical ICU. During the first 2-year period mupirocin ointment was included in the MRSA control programme; during the second, mupirocin was not used. The main endpoint was the number of endogenous ICU-acquired infections with MRSA.
The number of endogenous acquired infections was significantly higher during the second period than during the first (11 versus 1; P = 0.02), although there was no significant difference in the total number of patients infected with MRSA between the two periods. We also observed that nasal MRSA decolonisation was significantly higher in the mupirocin period than in mupirocin-free period (P = 0.002).
Our findings suggest that intranasal mupirocin can prevent endogenous acquired MRSA infection in an ICU. Further double-blind, randomised, placebo-controlled studies are needed to demonstrate its cost-effectiveness and its impact on resistance.</description><subject>Administration, Intranasal</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Cross Infection - prevention & control</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Intensive Care Units</subject><subject>Length of Stay</subject><subject>Methicillin Resistance</subject><subject>Mupirocin - administration & dosage</subject><subject>Mupirocin - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Staphylococcal Infections - prevention & control</subject><subject>Staphylococcus aureus - isolation & purification</subject><issn>1364-8535</issn><issn>1466-609X</issn><issn>1364-8535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kktr3DAQx0VpadJt-xGK6aE3t3pYknUplJA-IJBDEuhNyONxV8GWXEleyLePl126TaGnGTSj339ehLxl9CNjrfoEICTjz8g5a5SqFTU_n6--UE3dSiHPyKuc7yllulXiJTlj0rRaGH1Oyl3GKg6VDyW54LIbq2mZfYrgQ1ViNSfcYSjVhGXrwY-jD3XC7HNx6-tNcfP2YYwQAZZcuSXhanwYEIqPYfX2YAzZ77ACl7Bagi_5NXkxuDHjm6PdkLuvl7cX3-ur628_Lr5c1V3TsFIbRyWnPaJgnaAc2g5FTxkA73uhqGoMOqQtGEU7prTR0HPHB8EMF4Z3IDbk84E7L92EPeC-ydHOyU8uPdjovH0aCX5rf8WdZUzLdh3VhpgDoPPxP4CnEYiTPaxi_fvhKJ7i7wVzsZPPgOPoAsYl27XgVjC6F3n_T-J9XFJYB2O5VkJLqeWJBinmnHD4UwSjdn8BJ9l3f_d8SjuuXDwCX1uwzg</recordid><startdate>20050601</startdate><enddate>20050601</enddate><creator>Muller, Arno</creator><creator>Talon, Daniel</creator><creator>Potier, Alexandre</creator><creator>Belle, Evelyne</creator><creator>Cappelier, Gilles</creator><creator>Bertrand, Xavier</creator><general>National Library of Medicine - MEDLINE Abstracts</general><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20050601</creationdate><title>Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units</title><author>Muller, Arno ; Talon, Daniel ; Potier, Alexandre ; Belle, Evelyne ; Cappelier, Gilles ; Bertrand, Xavier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b441t-9a0520dee31b302c8be3d01cc2dd360649eae08c960b16797cd2a2f3192392bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Intranasal</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Cross Infection - prevention & control</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Intensive Care Units</topic><topic>Length of Stay</topic><topic>Methicillin Resistance</topic><topic>Mupirocin - administration & dosage</topic><topic>Mupirocin - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Staphylococcal Infections - prevention & control</topic><topic>Staphylococcus aureus - isolation & purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muller, Arno</creatorcontrib><creatorcontrib>Talon, Daniel</creatorcontrib><creatorcontrib>Potier, Alexandre</creatorcontrib><creatorcontrib>Belle, Evelyne</creatorcontrib><creatorcontrib>Cappelier, Gilles</creatorcontrib><creatorcontrib>Bertrand, Xavier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muller, Arno</au><au>Talon, Daniel</au><au>Potier, Alexandre</au><au>Belle, Evelyne</au><au>Cappelier, Gilles</au><au>Bertrand, Xavier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units</atitle><jtitle>Critical care (London, England)</jtitle><addtitle>Crit Care</addtitle><date>2005-06-01</date><risdate>2005</risdate><volume>9</volume><issue>3</issue><spage>R246</spage><epage>R250</epage><pages>R246-R250</pages><artnum>R246</artnum><issn>1364-8535</issn><eissn>1466-609X</eissn><eissn>1364-8535</eissn><abstract>Methicillin-resistant Staphylococcus aureus (MRSA) causes severe morbidity and mortality in intensive care units (ICUs) worldwide. The purpose of this study was to determine whether intranasal mupirocin prophylaxis is useful to prevent ICU-acquired infections with MRSA.
We conducted a 4-year observational retrospective study in a 15-bed adult medical ICU. During the first 2-year period mupirocin ointment was included in the MRSA control programme; during the second, mupirocin was not used. The main endpoint was the number of endogenous ICU-acquired infections with MRSA.
The number of endogenous acquired infections was significantly higher during the second period than during the first (11 versus 1; P = 0.02), although there was no significant difference in the total number of patients infected with MRSA between the two periods. We also observed that nasal MRSA decolonisation was significantly higher in the mupirocin period than in mupirocin-free period (P = 0.002).
Our findings suggest that intranasal mupirocin can prevent endogenous acquired MRSA infection in an ICU. Further double-blind, randomised, placebo-controlled studies are needed to demonstrate its cost-effectiveness and its impact on resistance.</abstract><cop>England</cop><pub>National Library of Medicine - MEDLINE Abstracts</pub><pmid>15987397</pmid><doi>10.1186/cc3512</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1364-8535 |
| ispartof | Critical care (London, England), 2005-06, Vol.9 (3), p.R246-R250, Article R246 |
| issn | 1364-8535 1466-609X 1364-8535 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1175886 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Administration, Intranasal Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Cross Infection - prevention & control Hospital Mortality Humans Intensive Care Units Length of Stay Methicillin Resistance Mupirocin - administration & dosage Mupirocin - therapeutic use Retrospective Studies Staphylococcal Infections - prevention & control Staphylococcus aureus - isolation & purification |
| title | Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T15%3A45%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20intranasal%20mupirocin%20to%20prevent%20methicillin-resistant%20Staphylococcus%20aureus%20infection%20in%20intensive%20care%20units&rft.jtitle=Critical%20care%20(London,%20England)&rft.au=Muller,%20Arno&rft.date=2005-06-01&rft.volume=9&rft.issue=3&rft.spage=R246&rft.epage=R250&rft.pages=R246-R250&rft.artnum=R246&rft.issn=1364-8535&rft.eissn=1466-609X&rft_id=info:doi/10.1186/cc3512&rft_dat=%3Cproquest_pubme%3E67983106%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=276375575&rft_id=info:pmid/15987397&rfr_iscdi=true |